| Cas No.: | 1639324-58-5 |
| Chemical Name: | Inclisiran |
| Synonyms: | CQQ59545BV;Cemdisiran;Inclisiran;ALN-PCSsc;Cemdisiran, terminal sugar modification-;Inclisiran, terminal sugar modification- |
| SMILES: | P(=O)(O)(O)OC[C@@H]1C[C@H](CN1C(CCCCCCCCCCC(NC(COCCC(NCCCNC(CCCCO[C@H]1[C@@H]([C@H]([C@H]([C@@H](CO)O1)O)O)NC(C)=O)=O)=O)(COCCC(NCCCNC(CCCCO[C@H]1[C@@H]([C@H]([C@H]([C@@H](CO)O1)O)O)NC(C)=O)=O)=O)COCCC(NCCCNC(CCCCO[C@H]1[C@@H]([C@H]([C@H]([C@@H](CO)O1)O)O)NC(C)=O)=O)=O)=O)=O)O |
| Formula: | C78H140N11O34P |
| M.Wt: | 1806.97328567505 |
| Purity: | >95% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Target: | PCSK9 |
| In Vitro: | Inclisiran is a double-stranded small RNA molecule that works by blocking the transcription of proprotein convertase subtilisin kexin 9 (PCSK-9), leading to a reduction of PCSK-9 levels in the hepatocytes, resulting in an increased expression of low-density lipoprotein (LDL) receptors in the hepatocyte membrane and, as a consequence, it reduces the circulating levels of LDL cholesterol (LDL-C). |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|